Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Change in Acquisitions & Divestments (2017 - 2018)

Aptevo Therapeutics (APVO) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $81.2 million as the latest value for Q3 2018.

  • Quarterly Change in Acquisitions & Divestments rose 237.73% to $81.2 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $177.4 million through Sep 2018, changed N/A year-over-year, with the annual reading at $90.2 million for FY2018, 27.59% up from the prior year.
  • Change in Acquisitions & Divestments hit $81.2 million in Q3 2018 for Aptevo Therapeutics, up from $52.8 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $81.2 million in Q3 2018 to a low of $8.1 million in Q1 2017.